Research programme: antibody drug conjugates - ABL Bio/Synaffix
Alternative Names: Antibody drug conjugates - ABL Bio/SynaffixLatest Information Update: 10 Nov 2023
At a glance
- Originator ABL Bio
- Developer ABL Bio; Synaffix
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer